Ligand Pharmaceuticals Incorporated (LGND) Stock Overview
Explore Ligand Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Ligand Pharmaceuticals Incorporated (LGND)
Key Financials
Key Financials
Market Cap
5.7B
P/E Ratio
36.71
EPS (TTM)
$8.34
ROE
0.16%
LGND Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Ligand Pharmaceuticals Incorporated (LGND) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 74.79, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $171.61.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 36.71 and a market capitalization of 5.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.